Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Amortization - Intangibles (2022 - 2026)

Axsome Therapeutics' Amortization - Intangibles history spans 5 years, with the latest figure at $1.6 million for Q1 2026.

  • On a quarterly basis, Amortization - Intangibles changed 0.0% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.4 million, a 0.0% change, with the full-year FY2025 number at $6.4 million, changed 0.27% from a year prior.
  • Amortization - Intangibles hit $1.6 million in Q1 2026 for Axsome Therapeutics, down from $1.6 million in the prior quarter.
  • Over the last five years, Amortization - Intangibles for AXSM hit a ceiling of $1.6 million in Q3 2022 and a floor of $926000.0 in Q2 2022.
  • Historically, Amortization - Intangibles has averaged $1.6 million across 5 years, with a median of $1.6 million in 2024.
  • Biggest five-year swings in Amortization - Intangibles: skyrocketed 71.6% in 2023 and later dropped 1.07% in 2025.
  • Tracing AXSM's Amortization - Intangibles over 5 years: stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025, then dropped by 2.18% to $1.6 million in 2026.
  • Business Quant data shows Amortization - Intangibles for AXSM at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.